State Key Laboratory of Oncogenes and Related GenesShanghai Cancer InstituteRenji HospitalShanghai Jiao Tong University School of MedicineShanghaiChina.
Liver Cancer InstituteZhongshan Hospital, and Key Laboratory of Carcinogenesis and Cancer Invasion (Ministry of Education)Fudan UniversityShanghaiChina.
Hepatology. 2021 Feb;73(2):644-660. doi: 10.1002/hep.31280.
Peroxisome proliferator-activated receptor-gamma (PPARγ) coactivator-1α (PGC1α) is a key regulator of mitochondrial biogenesis and respiration. PGC1α is involved in the carcinogenesis, progression, and metabolic state of cancer. However, its role in the progression of hepatocellular carcinoma (HCC) remains unclear.
In this study, we observed that PGC1α was down-regulated in human HCC. A clinical study showed that low levels of PGC1α expression were correlated with poor survival, vascular invasion, and larger tumor size. PGC1α inhibited the migration and invasion of HCC cells with both in vitro experiments and in vivo mouse models. Mechanistically, PGC1α suppressed the Warburg effect through down-regulation of pyruvate dehydrogenase kinase isozyme 1 (PDK1) mediated by the WNT/β-catenin pathway, and inhibition of the WNT/β-catenin pathway was induced by activation of PPARγ.
Low levels of PGC1α expression indicate a poor prognosis for HCC patients. PGC1α suppresses HCC metastasis by inhibiting aerobic glycolysis through regulating the WNT/β-catenin/PDK1 axis, which depends on PPARγ. PGC1α is a potential factor for predicting prognosis and a therapeutic target for HCC patients.
过氧化物酶体增殖物激活受体-γ(PPARγ)共激活因子-1α(PGC1α)是线粒体生物发生和呼吸的关键调节因子。PGC1α 参与癌症的发生、发展和代谢状态。然而,其在肝细胞癌(HCC)进展中的作用尚不清楚。
在本研究中,我们观察到 PGC1α 在人 HCC 中下调。一项临床研究表明,PGC1α 低表达与生存率降低、血管侵犯和肿瘤体积增大相关。PGC1α 通过 WNT/β-连环蛋白通路下调丙酮酸脱氢酶激酶同工酶 1(PDK1)抑制 HCC 细胞的迁移和侵袭,而 PPARγ 的激活诱导了 WNT/β-连环蛋白通路的抑制。
PGC1α 低表达表明 HCC 患者预后不良。PGC1α 通过调节 WNT/β-连环蛋白/PDK1 轴抑制有氧糖酵解来抑制 HCC 转移,这依赖于 PPARγ。PGC1α 是预测预后的潜在因素,也是 HCC 患者的治疗靶点。